UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO
UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO
The Study Results are Published in the Journal of Urology Online
研究結果已發佈在《泌尿學雜誌》在線版上
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO (n=41, 20 of whom entered the long-term follow-up study), the median duration of response was 47.8 months (median follow-up 28.1 months [95% CI 13.1, 57.5]). The study results are published online in the Journal of Urology.
烏龍製藥有限公司（納斯達克：URGN）是一家致力於開發和商業化治療尿路上皮和特殊癌症的新型解決方案的生物技術公司，今天強調了針對JELMYTO（美託黴素）進行的長期隨訪研究結果，該藥物被FDA批准用於治療成人低級別上尿路尿路上皮癌（LG-UTUC）。在經過JELMYTO的初次化學消融後在OLYMPUS試驗中實現完全緩解的患者中（n=41，其中20人進入了長期隨訪研究），緩解的中位持續時間爲47.8個月（中位隨訪28.1個月[95% CI 13.1, 57.5]）。研究結果已在線發佈在《泌尿學雜誌》上。
譯文內容由第三人軟體翻譯。
